Sie suchten nach: biotechnology (Holländisch - Dänisch)

abbott biotechnology ltd.
abbott biotechnology ltd.

abbott biotechnology deutschland gmbh max-planck-ring 2 es
lg abbott biotechnology deutschland gmbh max- planck- ring 2

roche diagnostics gmbh, pharma biotechnology production nonnenwald 2 82372 penzberg duitsland
roche diagnostics gmbh, pharma biotechnology production nonnenwald 2 82372 penzberg tyskland

de eerste twee initiatieven van het forum "biotechnology and finance"zullen zijn:
de to første initiativer fra "biotechnology and finance" bliver: •gennemførelse af "biotechnology and finance"­undersøgelsen, der skal klar­lægge bioteknologiens finansieringsbehov,

abbott biotechnology deutschland gmbh max-planck-ring 2 d-65205 wiesbaden duitsland
abbott biotechnology deutschland gmbh max- planck- ring 2 d - 65205 wiesbaden tyskland

het vormt een aanvulling op het door de european biotechnology information project van de british library verzamelde materiaal.
det er en af de største samlinger af materiale af denne art. der findes en ajourføring af materiale indsamlet af european biotechnology information project ved the british library.

abbott biotechnology deutschland gmbh er max-planck-ring 2 ng d-65205 wiesbaden duitsland t la
ret abbott biotechnology deutschland gmbh max- planck- ring 2 d – 65205 wiesbaden

deze wereldprimeur kon worden gerealiseerd in het kader van het bap-programma (biotechnology action programme).
dette gennembrud fandt sted inden for rammerne af bap­program­met (biotechnology action programme).

concept-rapporten concept paper on gene therapy concept paper on the development of a cpmp guideline on comparability of biotechnology-derived products
konceptdokumenter concept paper om gene therapy concept paper on the development of a cpmp guideline on comparability of biotechnology- derived products

de voor de veiligheidscontrole van bt11 gebruikte methoden waren ook in overeenstemming met de onlangs door de wetenschappelijke stuurgroep opgestelde richtsnoeren voor de beoordeling van ggo's en genetische gemodificeerde levensmiddelen en diervoeders en met de codex principles and guidelines on foods derived from biotechnology.
den metodologi, der blev anvendt ved sikkerhedsvurderingen af bt11, var ligeledes i overensstemmelse med den videnskabelige styringskomités seneste retningslinjer for vurdering af gmo'er og genetisk modificerede fødevarer og foderstoffer og med codex alimentarius' principper og retningslinjer for fødevarer fremstillet ved anvendelse af bioteknologi.

stu­dies on the socio­economic impact of biotechnology geeft een overzicht van de standpunten uit verschillende rechtssystemen in zeven lidstaten van de eu plus canada, japan, iran, israël, polen, rusland en tunesië.
bogen indeholder sammenligninger af de vigtigste aspekter af alle eu­medlemssta­ter, andre europæiske lande, usa, canada, japan og sng: kat.:

63) note for guidance on photosafety testing; points to consider document on the need for assessment of reproductive toxicity in the development of human insulin analogues discussion paper on environmental risk assessments of non-gmo containing medicinal products for human use non-clinical documentation of medicinal products with ‘ well-established use’ note for guidance on the need for non-clinical testing of pharmaceuticals in juvenile animals discussion paper on the non-clinical safety studies to support single low dose clinical screening studies in man note for guidance on specification limits for residues for heavy metal catalysts in medicinal products points to consider on xenogeneic cell therapy note for guidance on comparability of biotechnology products pre-clinical and clinical issues points to consider on the assessment of the potential for qt interval prolongation by non-cardiovascular medicinal products note for guidance on risk assessment of medicinal products on human reproductive and development toxicities: from data to labelling
63) note for guidance on photosafety testing points to consider document on the need for assessment of reproductive toxicity of human insulin analogues discussion paper on environmental risk assessments of non- gmo containing medicinal products for human use non- clinical documentation of medicinal products with ‘ well- established use ’ note for guidance on the need for non- clinical testing of pharmaceuticals in juvenile animals discussion paper on the non- clinical safety studies to support single low dose clinical screening studies in man note for guidance on specification limits for residues for heavy metal catalysts in medicinal products points to consider on xenogeneic cell therapy note for guidance on comparability of biotechnology products pre- clinical and clinical issues points to consider on the assessment of the potential for qt interval prolongation by non- cardiovascular medicinal products note for guidance on risk assessment of medicinal products on human reproductive and development toxicities: from data to labelling